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Objectives We examined the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization
Effectiveness) database to understand the impact and pathophysiology of renal dysfunction in patients hospital-
ized with advanced decompensated heart failure (HF).
Background Baseline renal insufficiency (RI) (estimated glomerular filtration rate [eGFR] 60 ml/min) and worsening renal
function (WRF) (1 serum creatinine [SCr] 0.3 mg/dl) during treatment of decompensated HF are associated
with adverse outcomes.
Methods We used a Cox proportional hazards model to evaluate the impact of renal function on 6-month outcomes. Re-
nal parameters were correlated with hemodynamic measurements. The impact of a strategy using pulmonary
artery catheter (PAC) guidance on WRF and outcomes in patients with baseline RI was compared with treatment
based on clinical assessment alone.
Results Baseline and discharge RI, but not WRF, were associated with an increased risk of death and death or rehospi-
talization. Among the hemodynamic parameters measured in patients randomized to the PAC arm (n  194),
only right atrial pressure correlated weakly with baseline SCr (r  0.165, p  0.03). There was no correlation
between baseline hemodynamics or change in hemodynamics and WRF. A PAC-guided strategy was associated
with less average increase in creatinine but did not decrease the incidence of defined WRF during hospitaliza-
tion or affect renal function after discharge relative to clinical assessment alone.
Conclusions Among patients with advanced decompensated HF, baseline RI impacts outcomes more than WRF. Poor for-
ward flow alone does not appear to account for the development of RI or WRF in these patients. The addition of
hemodynamic monitoring to clinical assessment does not prevent WRF or improve renal function after dis-
charge. (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization; NCT00000619).
(J Am Coll Cardiol 2008;51:1268–74) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.072d
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chere is increasing awareness of the interdependency be-
ween the heart and kidney in patients with heart failure. A
umber of studies have shown that abnormal renal function
s associated with poor outcomes in patients with left
entricular dysfunction and heart failure (1–3). Moreover,
hen patients are hospitalized with heart failure exacerba-
ion, even small changes in renal function can influence
rognosis (4,5). Although the so-called “cardio-renal syn-
rom *Brigham and Women’s Hospital, Harvard Medical School, Boston, Massa-
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lorida College of Medicine, Gainesville, Florida; §Ahmanson-UCLA Cardiomy-
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outhwestern Medical School, Dallas, Texas. The ESCAPE trial was a multicenter
rial supported by contract N01-HV-98177 from the National Heart, Lung, and
lood Institute to Duke University Medical Center.p
Manuscript received May 30, 2007; revised manuscript received August 9, 2007,
ccepted August 13, 2007.rome” is defined as the interaction of the heart and kidney
hat leads to diuretic resistance and worsening renal func-
ion, its pathophysiology is poorly understood.
See page 1275
The ESCAPE (Evaluation Study of Congestive Heart
ailure and Pulmonary Artery Catheterization Effective-
ess) trial prospectively compared the strategy of pulmonary
rtery catheter–guided therapy (PAC) with treatment based
n clinical assessment alone (CLIN) with regard to short-
erm and 6-month outcomes in patients hospitalized with
dvanced heart failure (6,7). The ESCAPE trial provides a
nique opportunity to evaluate the relationship between
ardiac hemodynamics and renal dysfunction in this patient
opulation. The current study is a post-hoc examination of
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April 1, 2008:1268–74 Cardiorenal Interactions in the ESCAPE Trialhe data from the ESCAPE trial to: 1) evaluate the measure
f renal function (i.e., admission creatinine/creatinine clear-
nce [CrCl], discharge creatinine/CrCl, or worsening renal
unction) that has the greatest influence on outcomes in the
dvanced heart failure population; 2) examine the relation-
hip between hemodynamic parameters and the above
entioned measures of renal function; and 3) assess the
mpact of pulmonary artery catheter–guidance on worsen-
ng renal function during heart failure hospitalization and
n short- and long-term outcomes in patients with baseline
enal insufficiency.
ethods
tudy population. The Institutional Review Boards of
articipating ESCAPE centers approved the study. A total
f 433 patients were enrolled at 26 sites. The inclusion and
xclusion criteria of patients enrolled in the ESCAPE trial
ave been previously described (6). For the current study,
atients with a left ventricular ejection fraction 30%,
ecent hospitalization or escalation of out-patient diuretic
herapy, and systolic blood pressure 125 mm Hg who
ere admitted to the hospital with at least 1 sign and 1
ymptom of heart failure, despite adequate treatment with
ngiotensin-converting enzyme inhibitors and diuretics,
ere included. Important exclusion criteria included a
reatinine 3.5 mg/dl, the use of dobutamine/dopamine
3 g/kg/min or milrinone before randomization, and
equirement for early right heart catheterization.
tudy design. Patients were randomized 1:1 to receive
herapy guided by clinical assessment and the PAC or
LIN. The treatment goal in the CLIN arm was resolution
f clinical signs and symptoms of congestion. The treatment
oal of the PAC arm was similar with the addition of
ulmonary capillary wedge pressure (PCWP) 15 mm Hg
nd right atrial pressure (RAP) 8 mm Hg. The protocol
id not specify drug selection, but the use of inotropic
gents was discouraged. Medications were titrated to avoid
rogressive renal dysfunction or symptomatic hypotension
7). The primary end point of the ESCAPE trial was days
live and out of the hospital for 6 months after randomiza-
ion (6,7). Secondary end points relevant to the present
tudy included 30-day mortality and length of stay (6,7).
his study is a post-hoc analysis of the renal and hemody-
amic data collected in the ESCAPE trial to gain further
nsight into cardio-renal interactions in the advanced heart
ailure population.
easures of renal function. In the ESCAPE trial, serum
reatinine (SCr) was measured at baseline, day of optimal
olume status (as judged by the physician), day 7 of
ospitalization, day of hospital discharge, and at 3 months
nd 6 months. For this study, we calculated the estimated
rCl (estimated glomerular filtration rate [eGFR]) by using
he modified Modification of Diet in Renal Disease equa-
ion (8,9). Worsening renal function was defined as an
ncrease in SCr from baseline to discharge0.3 mg/dl. This Salue was chosen because it has
reviously been demonstrated to
ave the maximum sensitivity
nd specificity for in-hospital
ortality and length of stay (5).
tatistical methods. Values are
resented as mean  SD. Con-
inuous variables were compared
ith the Student t test for nor-
ally distributed and the Wilcox-
n rank sum test for not normally
istributed variables, respec-
ively. Discrete variables were
ompared with the use of chi-
quare analysis. Univariate Cox
roportional hazards regression
nalysis was used to test the
rognostic value of each renal parameter. Individuals alive
nd not hospitalized at 180 days were censored. The hazard
atios for SCr and eGFR were calculated for increments of
.3 mg/dl and decrements of 10 ml/min, respectively. The
azard ratio for worsening renal function was calculated by
reating it as a dichotomous variable with a positive change
eing an increase in SCr 0.3 mg/dl from baseline to
ischarge. To verify the prognostic value of worsening renal
unction, the hazard ratio for death and death or rehospi-
alization also was assessed for a decline in eGFR 25%
rom baseline to discharge. In the PAC patients, baseline
emodynamic indexes were correlated with baseline SCr,
GFR, and worsening renal function using the Pearson’s
orrelation coefficient for normally distributed variables and
pearman’s correlation coefficient for not-normally distrib-
ted data. Changes in hemodynamic indices during the
ospitalization were also correlated with worsening renal
unction using the methods described previously. Univariate
redictors of worsening renal function were evaluated by
ogistic regression analysis. Significant predictors were then
ested in a step-wise multivariate model. A p value 0.05
as considered statistically significant.
esults
aseline characteristics. A total of 433 patients were
nrolled in the ESCAPE trial. The complete baseline
haracteristics of the study population have been published
reviously (7). Baseline characteristics pertinent to this
nalysis are presented in Table 1. Importantly, the preva-
ence of hypertension and diabetes and the use of baseline
edications, including dosages of loop-diuretics, did not
iffer between the 2 treatment groups. Baseline blood
ressure and renal function also were similar between the 2
tudy arms.
easures of renal function and outcomes. For the pa-
ients enrolled in the ESCAPE trial, the median baseline
Abbreviations
and Acronyms
CLIN  clinical
assessment–guided
treatment strategy
CrCl  creatinine clearance
eGFR  estimated
glomerular filtration rate
PAC  pulmonary artery
catheter–guided treatment
strategy
PCWP  pulmonary
capillary wedge pressure
RAP  right atrial pressure
SCr  serum creatinineCr was 1.50 mg/dl and the median baseline eGFR was
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Cardiorenal Interactions in the ESCAPE Trial April 1, 2008:1268–741.4 ml/min. The median discharge SCr and median
ischarge eGFR were 1.55 mg/dl and 73.9 ml/min, respec-
ively. In the ESCAPE trial, 45% of enrolled patients had
ome deterioration in their renal function at the time of
ischarge relative to baseline with mean and median
hanges in SCr from baseline to discharge of 0.07 and 0.00
l/min, respectively. A total of 110 (29.5%) patients had an
ncrease in SCr 0.3 mg/dl relative to baseline.
The association between various measures of renal func-
ion and outcomes was tested. As shown in Table 2, both
aseline and discharge renal function were predictive of
-month outcomes. The risk of death and death or rehos-
italization at 6 months increased with increasing SCr and
ecreasing eGFR. However, a change in SCr of0.3 mg/dl
r a decline in eGFR of 25% compared with baseline was
ot associated with an increased risk of death or death or
ehospitalization at 6 months. Interestingly, baseline renal
unction appeared to be more predictive of long-term out-
omes than worsening renal function during hospitalization.
emodynamics and renal function. In an effort to under-
tand the relationship between cardiac and renal function in
atients with advanced heart failure, we correlated baseline
Cr and eGFR with baseline hemodynamic measurements
n patients randomized to the PAC arm (n  194). There
aseline Characteristics of the Study Population
Table 1 Baseline Characteristics of the Study Population
Characteristic
CLIN
(n  218)
PAC
(n  215) p Value
Age, yrs 56 14 56 14 0.80
Hypertension, % 47 48 0.78
Diabetes mellitus, % 34 33 0.68
ACE-I/ARB, % 90 91 0.66
Beta-blockers, % 59 65 0.19
Aldosterone antagonist, % 44 44 0.98
Loop diuretic, mg/day 332 392 306 530 0.08
Weight, kg 85.6 20.3 85.7 21.8 0.86
Systolic BP, mm Hg 106 15 106 17 0.77
BUN, mg/dl 36 24 34 21 0.88
Serum creatinine, mg/dl 1.5 0.6 1.5 0.6 0.50
eGFR, ml/min 76.1 40.6 72.8 36.4 0.79
CE-I/ARB  angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; BP  blood
ressure; BUN  blood urea nitrogen; CLIN  clinical assessment–guided therapy; eGFR 
stimated glomerular filtration rate; PAC  pulmonary artery catheter–guided therapy.
elationship Between Renal Parameters and 6-Month Outcomes
Table 2 Relationship Between Renal Parameters and 6-Month
Time to Death
HR* 95% CI
Baseline SCr 1.20 1.11–1.29
Baseline eGFR 1.25 1.13–1.38
Discharge SCr 1.30 1.20–1.41
Discharge eGFR 1.28 1.14–1.43
0.3 mg/dl1 SCr† 1.31 0.81–2.10
25%2 eGFR‡ 1.49 0.91–2.44
Hazard ratio (HR) calculated per 0.3-mg/dl increments in serum creatinine (SCr) and per 10-m
) †an increase in SCr 0.3 mg/dl; and 2) ‡a decrease in eGFR 25% from baseline to discharge, is tre
CI  confidence interval.as no correlation between baseline SCr or eGFR and
aseline PCWP, cardiac index, or systemic vascular resis-
ance (data not shown). There was however, a weak, but
ignificant, correlation between baseline SCr and RAP (r 
.165, p  0.03) and similarly between baseline eGFR and
AP (r  0.195, p  0.01).
Among the 194 patients randomized to PAC, there was
o correlation between baseline hemodynamic parameters
RAP, PCWP, cardiac index, and SVR) and worsening renal
unction (data not shown). Similarly, there was no correlation
etween change in hemodynamic parameters during hospital-
zation and worsening renal function (data not shown).
ffect of PAC on outcomes in patients stratified by
aseline renal function. To evaluate whether PAC im-
roved outcomes in high-risk patients with baseline renal
nsufficiency, we divided the patient population into those
ith eGFR 60 ml/min (n  117) and 60 ml/min (n 
56). The proportion of patients with eGFR 60 ml/min
as similar in the 2 treatment arms (31.7% in PAC vs. 31%
n CLIN). A pulmonary artery catheter–guided strategy was
ot associated with improved 6-month outcomes of death
r death or rehospitalization in either group, relative to a
trategy based on clinical examination alone (Table 3).
The impact of PAC on in-hospital mortality was not
valuated because there were only 8 in-hospital deaths in the
SCAPE trial (7). With regard to short-term outcomes,
AC did not affect 30-day mortality or length of stay in
ither eGFR group relative to the CLIN arm. Among
atients with eGFR60 ml/min, 3 of 59 patients died at 30
ays compared with 6 of 58 in the CLIN arm (p  0.30).
imilarly, among patients with an eGFR60 ml/min, there
as no difference in 30 day mortality between patients
andomized to the PAC (5 of 127) and CLIN (4 of 129)
rms (p  0.72). Length of stay did not differ with eGFR
r treatment strategy. For patients with eGFR60 ml/min,
he median length of stay was 6 days in the CLIN arm and
days in the PAC arm (p  0.88) and for those with an
GFR 60 ml/min, it was 6 days in both arms (p  0.20).
hus, the addition of PAC neither shortened hospitaliza-
ion nor improved outcomes in patients with baseline renal
nsufficiency compared to CLIN.
mes
Time to Death or Rehospitalization
Value HR* 95% CI p Value
.0001 1.14 1.08–1.21 0.0001
.0001 1.10 1.05–1.15 0.0001
.0001 1.14 1.08–1.21 0.0001
.0001 1.09 1.03–1.15 0.002
.27 1.26 0.96–1.64 0.09
.12 1.06 0.79–1.43 0.69
ecrements in estimated glomerular filtration rate (eGFR). Worsening renal function, defined as:Outco
p
0
0
0
0
0
0
l/min d
ated as a dichotomous variable.
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April 1, 2008:1268–74 Cardiorenal Interactions in the ESCAPE Trialredictors of worsening renal function in the ESCAPE
rial. It has previously been suggested that an increase in
reatinine during the treatment of decompensated heart
ailure is associated with adverse outcomes (4,5). To evalu-
te why patients with baseline renal insufficiency might have
 worse prognosis, we evaluated the predictors of worsening
arameters of renal function in the ESCAPE trial. Univar-
ate analysis of the ESCAPE database demonstrated that
aseline renal insufficiency was not predictive of the devel-
pment of worsening renal function during the treatment of
ecompensated heart failure (p  0.68). However, a previ-
us history of hypertension (p  0.0007), a previous history
f diabetes mellitus (p  0.03), and in-hospital thiazide
iuretic use (p  0.0001) were associated with an increase in
Cr 0.3 mg/dl relative to baseline. Interestingly, neither
n-hospital intravenous vasodilator use (p  0.18) nor
n-hospital loop diuretic dosage (p  0.59) were predictive
f the development of worsening renal function. Although,
n average, PAC was associated with significantly less
eterioration in renal function relative to the CLIN arm (p
 0.02), the proportion of patients with an increase in SCr
f 0.3 mg/dl was similar in both the PAC and CLIN arms
26% vs. 33%, p  0.18). Furthermore, SCr was similar in
he PAC and CLIN arms at discharge (1.52 mg/dl vs. 1.58
g/dl, p  0.38) and 6 months’ follow up (1.49 mg/dl vs.
.59 mg/dl, p  0.38). Only hypertension (p  0.002) and
n-hospital thiazide use (0.0001) remained predictive of
orsening renal function in the multivariable analysis.
Although baseline SCr/eGFR was not a predictor of
orsening renal function in this analysis, previous studies
ave suggested that baseline renal insufficiency is a risk
actor for the development of worsening renal function
uring heart failure hospitalization. Therefore, we evaluated
he impact of PAC on worsening renal function in patients
tratified by baseline eGFR. Approximately, one-third of
he patients with baseline eGFR 60 ml/min and 28% of
hose with baseline eGFR 60 ml/min developed worsen-
ng renal function (p  0.28). The PAC did not decrease
he incidence of worsening renal function in either eGFR
roup (Fig. 1).
n-hospital medication use based on baseline renal func-
ion and study arm. To see whether treatment differences
ight have contributed to the worse outcomes observed in
atients with baseline renal insufficiency, we compared
n-hospital medication use between patients with a low
Impact of PAC on 6-Month Outcomes in Patients
Table 3 Impact of PAC on 6-Month Outcomes
End Point
Subgroup
(eGFR, ml/min)
Death 60
60
Death or rehospitalization 60
60
The p value for the interaction between eGFR and treatment was not si
Abbreviations as in Tables 1 and 2.GFR and those with normal renal function. Patients withaseline renal insufficiency (eGFR 60 ml/min) were more
ikely to be treated with thiazide diuretics in addition to
oop diuretics (39% vs. 26%, p  0.02). Although not
tatistically significant, there was also a trend for higher
asodilator (35% vs. 28%) and inotrope use (51% vs. 43%) in
atients with baseline renal dysfunction. Among these
atients, those randomized to PAC were less likely to
eceive thiazides, whereas those treated according to clinical
ssessment alone tended to have less vasodilator and ino-
rope use (Table 4). These data highlight the need for
dditional agents to overcome diuretic resistance in patients
ith baseline renal insufficiency, regardless of treatment
trategy.
iscussion
his analysis from the ESCAPE trial shows that impaired
aseline renal function, but not worsening renal function, is
trongly associated with adverse outcomes in advanced heart
ailure patients admitted with acute decompensation. De-
pite this strong inter-relationship between cardiac and renal
isease, of the hemodynamic parameters measured, only RAP
ad a weak correlation with baseline renal function. Attempts
o optimize measured hemodynamics and end-organ perfu-
ion using PAC did not improve renal function or outcomes
Figure 1 Impact of PAC on Worsening Renal Function
in Patients Stratified by Baseline Renal Function
Patients were stratified based on their admission estimated glomerular filtra-
tion rate (eGFR) into those with (eGFR 60 ml/min) and without (eGFR 60
ml/min) baseline renal insufficiency. A pulmonary artery catheter-guided treat-
ment strategy (PAC) did not reduce the incidence of worsening renal function
(defined as a 0.3 mg/dl increase in serum creatinine from baseline to dis-
charge) in either eGFR group relative to a strategy based on clinical assess-
ment alone (CLIN).
fied by Baseline Renal Function
atients Stratified by Baseline Renal Function
HR for PAC
Versus CLIN 95% CI p Value
1.45 0.92–2.30 0.11
0.88 0.54–1.44 0.61
1.17 0.90–1.52 0.23
0.92 0.71–1.20 0.55
t for both death (p 0.18) and death or rehospitalization (p 0.26).Strati
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Cardiorenal Interactions in the ESCAPE Trial April 1, 2008:1268–74n this advanced heart failure population, relative to CLIN.
hese results suggest that in patients with advanced decom-
ensated heart failure the relationship between heart failure
nd renal dysfunction is more complex than hemodynamics
lone.
Several previous studies have evaluated the contribution
f renal insufficiency to outcome in patients with left
entricular dysfunction and heart failure. In patients with
symptomatic and symptomatic left ventricular dysfunction
rom the SOLVD (Studies Of Left Ventricular Dysfunction)
rial, Dries et al. (2) showed that moderate renal insufficiency
eGFR 60 ml/min) was associated with increased total and
ump failure mortality and the combined end point of heart
ailure hospitalization and death. In the Digitalis Interven-
ion Trial, which included largely New York Heart Asso-
iation functional class II to III heart failure patients,
hlipak et al. (10) reported a steep increase in annual
ortality when eGFR decreased to 50 ml/min/1.73 m2.
cAlister et al. (11) evaluated a prospective cohort of 754
atients referred to their clinic with systolic or diastolic
eart failure. Over a median follow-up period of 926 days,
hey found that estimated CrCl was an independent pre-
ictor of survival with a 1% increase in mortality for every 1
l/min decrease in eGFR. Hillege et al. (12) reported
imilar findings from substudies of the PRIME-II (Second
rospective Randomized Study of Ibopamine on Mortality
nd Efficacy) (1) and CHARM (Candesartan in Heart
ailure—Assessment of Reduction in Mortality and Mor-
idity) trials. The results of this analysis concur with these
tudies and confirm that in patients admitted with decom-
ensated heart failure, the presence of baseline renal insuf-
ciency portends a poor prognosis.
Worsening renal function during hospitalization also has
een associated with greater in-hospital, 30-day, and
-month mortality, longer lengths of stay, and higher
ospital costs (4,13,14). Previous retrospective analyses have
dentified advanced age, hypertension, diabetes, pre-existing
enal insufficiency, and higher doses of loop diuretics as
otential risk factors contributing to the development of
orsening renal function (4,14,15). To our knowledge, this
s the first analysis to prospectively evaluate the incidence of
orsening renal function and its impact on mortality and
ehospitalization in the advanced heart failure population.
s in previous studies, the incidence of worsening renal
n-Hospital Medication Use by Baseline Renal Function and Treatm
Table 4 In-Hospital Medication Use by Baseline Renal Function
eGFR <60 ml/min
CLIN (n  58) PAC (n  59)
Loop diuretics, % 91 90
Thiazide diuretics, % 48 29
Intravenous vasodilators, % 28 42
Intravenous inotropes, % 46 57
Total loop diuretic dose, mg 286.4 466.7
bbreviations as in Table 1.unction (defined as an increase in SCr 0.3 mg/dl) was ipproximately 30% (4,14). Similarly, hypertension, diabetes,
nd the use of thiazide diuretics were associated with the
evelopment of worsening renal function. However, in this
nalysis worsening renal function did not predict an inferior
rognosis in this patient population. This may have impor-
ant clinical implications, because the current trend in
n-hospital management is to curtail diuresis and withdraw
mportant life-prolonging medications, such as angiotensin-
onverting enzyme inhibitors, in the face of worsening renal
unction during hospitalization. Perhaps this outcome is
nevitable in patients with risk factors such as hypertension
nd diabetes and should be viewed as a marker of intrinsic
enal disease rather than a signal to limit adequate diuresis
nd symptom resolution. Further prospective studies are
eeded to clarify the prognostic significance of worsening
enal function relative to baseline renal insufficiency in the
dvanced heart failure population.
Renal dysfunction, in the absence of heart failure, carries
poor prognosis (16). It is not surprising, therefore, that the
oncomitant presence of 2 diseases with poor outcomes
ompounds the mortality of either alone. However, it is
nteresting to examine the potential reasons why patients
ith advanced heart failure have an increased incidence of
oncomitant renal dysfunction (17). The ESCAPE trial
rovides a unique opportunity to better understand the
elationship between cardiac and renal dysfunction at a
emodynamic level. The lack of correlation between base-
ine renal function and cardiac index in this study suggests
hat renal insufficiency that frequently accompanies heart
ailure is not merely a consequence of poor forward flow. In
he ESCAPE trial, PAC improved cardiac index signifi-
antly from 1.9  0.6 l/min/m2 to 2.4  0.7 l/min/m2 (p 
.01) (7). Yet, hemodynamic optimization with PAC did
ot improve renal function or long-term outcomes in this
atient population. Similarly, it has been proposed that
xcessive vasodilation with afterload reducing agents con-
ributes to renal dysfunction in this advanced heart failure
opulation. Once again, the lack of correlation between
VR and baseline renal function suggests that this is
robably not always the case. The weak positive correlation
ith RAP observed in this study does, however, suggest that
iventricular failure rather than isolated left ventricular
ailure may be a marker of more advanced cardiac disease
nd thus may contribute to the development of renal
trategy
Treatment Strategy
eGFR >60 ml/min
p Value CLIN (n  129) PAC (n  127) p Value
0.78 92 93 0.84
0.04 29 24 0.41
0.12 16 43 0.001
0.23 41 44 0.65
0.38 240.1 272.7 0.59ent S
andnsufficiency in these patients. Similarly, baseline hemody-
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April 1, 2008:1268–74 Cardiorenal Interactions in the ESCAPE Trialamics or change in hemodynamics with treatment did not
orrelate with the development of worsening renal function
uring hospitalization. This again suggests that a “pre-
enal” etiology, either on the basis of low forward flow,
verdiuresis, or excessive vasodilation is unlikely to be the
rimary determinant of worsening renal function.
Other possible explanations for the increased incidence of
enal insufficiency in patients with advanced heart failure
nclude the observation that patients with renal dysfunction
end to be older and have a higher prevalence of comorbidi-
ies such as hypertension and diabetes that cause both
ntrinsic renal disease and heart failure (17). Second, the
resence of these diseases, especially hypertension, disrupts
enal blood flow autoregulation, making the kidney more
usceptible to developing worsening renal function during
he treatment of heart failure. In patients with a history of
ypertension, the renal autoregulatory curve shifts to the
ight such that decreases in mean arterial pressure as a
onsequence of decreased forward flow, vasodilator medica-
ions, or diuretics result in decreased intraglomerular pres-
ure and GFR at blood pressures that would not affect renal
unction in normal subjects (18,19). This is corroborated by
ur observation that hypertension and thiazide diuretics in
ddition to loop diuretics are associated with worsening
enal function. Unfortunately, the number of subjects with
ypertension and diabetes in ESCAPE was too small to
valuate whether PAC improves renal function and out-
omes in this subset of patients. We attempted to overcome
his limitation by assessing the impact of PAC in patients
ith baseline renal insufficiency compared to those with
ormal renal function. Our results demonstrate that PAC
oes not reduce the incidence of worsening renal function or
mprove renal function and outcomes in patients with
aseline renal insufficiency. Coupled with the hemodynamic
nalysis, these results suggest that risk factors for intrinsic
enal disease probably make the kidney more susceptible to
ardiac compromise and thus have a greater influence on
ardiorenal interactions than low output alone. Third,
aroreceptor dysfunction and neurohormonal activation,
uch as that seen with advanced heart failure, results in
nappropriate vasoconstriction of the pre-glomerular affer-
nt arterioles, thus decreasing renal blood flow and GFR
19). Improving hemodynamics, without necessarily altering
he neurohormonal milieu, probably does not affect renal
unction or long-term outcomes in this patient population.
n the ESCAPE trial, a similar proportion of patients in the
AC arm were on neurohormonal modifiers such as
ngiotensin-converting enzyme inhibitors and beta-blockers
t the time of hospital discharge as in the CLIN arm (7).
his may explain why PAC had no impact on long-term
enal function or prognosis relative to CLIN.
tudy limitations. There are several limitations to this
tudy. First, the ESCAPE trial was not designed to study
atients with end stage or advanced renal insufficiency and
he entry criteria excluded patients with creatinine 3.5
g/dl. Second, there were insufficient patients with comor-idities that contribute to intrinsic renal disease, and thus it
as not possible to assess whether a specific treatment
trategy would be beneficial in this high-risk population. It
s possible that the impact of PAC may have been more
pparent in a population selected for intrinsic renal disease.
hird, changes in renal function were not pre-specified end
oints of the ESCAPE trial and how the clinicians chose to
odify therapy might have been different among investiga-
or sites. For example, some investigators may have chosen
o modify a clinical or hemodynamic parameter at the
xpense of worsening renal function. The opposite may have
lso been true. However, the data collection was not
esigned to determine how renal function was used to guide
herapy. Unfortunately, this is true of all studies that have
valuated renal function during heart failure treatment and
rospective studies in this area are needed to evaluate
hether worsening renal function per se impacts outcomes.
ourth, SCr and eGFR may not be the most accurate
arkers for acute changes in renal function. Other markers
uch as cystatin-C (20) were not measured in the ESCAPE
rial. Finally, a strategy that adjusts treatment based on a
ery limited monitoring period in hospital may not be
ufficient to affect renal function or outcomes in the months
fter discharge, when changes in diuretic doses are frequent
nd are made in response to clinical assessment alone (21).
onclusions
his analysis of the ESCAPE trial suggests that in patients
ospitalized with advanced decompensated heart failure,
aseline renal insufficiency impacts prognosis more than
orsening renal function during hospitalization. The lack of
orrelation between measured hemodynamic parameters
nd renal function suggests that poor forward flow may
ontribute to but is not the primary cause of renal dysfunc-
ion in patients with advanced heart failure. Accordingly,
emodynamic optimization with PAC did not reduce the
ncidence of worsening renal function or improve renal
unction or outcomes, even among patients with baseline
enal insufficiency, in this study. Advanced heart failure
atients with conditions such as hypertension and diabetes
hat contribute to the development of intrinsic renal disease
nd disrupt renal autoregulation may be at increased risk for
dverse outcomes. Efforts to reverse or improve renal
mpairment in high-risk populations during the manage-
ent of decompensated heart failure warrant further study.
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